ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.122A>G (p.His41Arg) (rs80357276)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000111820 SCV000244297 pathogenic Breast-ovarian cancer, familial 1 2015-08-10 reviewed by expert panel curation IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 5 based on posterior probability = 0.995
Invitae RCV000047383 SCV000075396 pathogenic Hereditary breast and ovarian cancer syndrome 2020-09-24 criteria provided, single submitter clinical testing This sequence change replaces histidine with arginine at codon 41 of the BRCA1 protein (p.His41Arg). The histidine residue is highly conserved and there is a small physicochemical difference between histidine and arginine. This variant is not present in population databases (ExAC no frequency). This variant has been observed in several individuals affected with breast and/or ovarian cancer, and reported to segregate with disease in two families (PMID: 15168169, 24489791). ClinVar contains an entry for this variant (Variation ID: 54166). This variant disrupts the p.His41 amino acid residue in BRCA1, one of eight highly-conserved Cys/His residues in the N-terminal RING domain (PMID: 22843421). It has been reported to affect BRCA1 protein function (PMID: 16403807, 23161852, 20103620, 21725363, 25823446, 30209399). For these reasons, this variant has been classified as Pathogenic.
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge RCV000111820 SCV000324990 pathogenic Breast-ovarian cancer, familial 1 2015-10-02 criteria provided, single submitter clinical testing
GeneDx RCV000484980 SCV000568437 pathogenic not provided 2016-05-24 criteria provided, single submitter clinical testing This pathogenic variant is denoted BRCA1 c.122A>G at the cDNA level, p.His41Arg (H41R) at the protein level, and results in the change of a Histidine to an Arginine (CAC>CGC). Using alternate nomenclature, this pathogenic variant would be defined as BRCA1 241A>G. This variant has been observed in at least one individual with breast cancer (Kawahara 2004). BRCA1 His41Arg has been associated with weakened BARD1 binding, centrosome amplification, and inhibition of ubiquitin ligase, single strand annealing (SSA), and homology directed recombination (HDR) activities (Morris 2006, Ransburgh 2010, Kais 2012, Towler 2013). Additionally, this variant was predicted to be pathogenic by a multifactorial model based on tumor pathology, segregation, and in silico analyses (Whiley 2014). BRCA1 His41Arg was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Histidine and Arginine share similar properties, this is considered a conservative amino acid substitution. BRCA1 His41Arg occurs at a position that is conserved in mammals and at an important zinc-ligating residue located within the RING domain and the binding domains of BARD1 and BRD7 (Narod 2004, Borg 2010, Harte 2010, Paul 2014). In silico analyses predict that this pathogenic variant is probably damaging to protein structure and function. The Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) expert panel classifies this variant as pathogenic (ClinVar). Based on currently available evidence, we consider this variant to be pathogenic.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000484980 SCV000600243 likely pathogenic not provided 2016-08-22 criteria provided, single submitter clinical testing
Ambry Genetics RCV000569789 SCV000660995 pathogenic Hereditary cancer-predisposing syndrome 2019-04-16 criteria provided, single submitter clinical testing The p.H41R pathogenic mutation (also known as c.122A>G), located in coding exon 2 of the BRCA1 gene, results from an A to G substitution at nucleotide position 122. The histidine at codon 41 is replaced by arginine, an amino acid with highly similar properties. This histidine is crucial in coordinating the Zinc atom, which controls the structure of the functionally important RING domain (Brzovic PS et al. Nat. Struct. Biol. 2001 Oct; 8(10):833-7; Brzovic PS et al. Proc. Natl. Acad. Sci. U.S.A. 2003 May; 100(10):5646-51). Several independent functional assays demonstrate that although this alteration may not disrupt binding of BRCA1 to BARD1, it significantly impacts its ubiquitin ligase activity, homology directed recombination activity, single strand annealing abilities and significantly increased centrosome amplification (Morris JR et al. Hum. Mol. Genet. 2006 Feb; 15(4):599-606; Ransburgh DJ et al. Cancer Res. 2010 Feb; 70(3):988-95; Towler WI et al. Hum. Mutat. 2013 Mar; 34(3):439-45; Caleca L et al. Cancers (Basel), 2019 Jan;11; Starita LM et al. Genetics, 2015 Jun;200:413-22; Starita LM et al. Am. J. Hum. Genet., 2018 Oct;103:498-508). In support of these defects being inconsistent with normal BRCA1 function, a high throughput genome editing haploid cell survival assay also found this alteration deleterious (Findlay GM et al. Nature, 2018 10;562:217-222). In a study that used multifactorial likelihood analysis to assess the pathogenicity of BRCA1/2 variants, this variant was considered pathogenic with a posterior probability of pathogenicity of 0.995, largely attributable to a strong co-segregation likelihood ratio (Whiley PJ et al. PLoS ONE 2014; 9(1):e86836; Park KS et al. Genet. Med., 2016 12;18:1250-1257). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this alteration is interpreted as a disease-causing mutation.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000047383 SCV000916704 pathogenic Hereditary breast and ovarian cancer syndrome 2018-01-25 criteria provided, single submitter clinical testing Variant summary: The BRCA1 c.122A>G (p.His41Arg) variant involves the alteration of a conserved nucleotide located in the Zinc finger, C3HC4 RING-type domain (IPR018957) (InterPro). 5/5 in silico tools predict a damaging outcome for this variant. Functional studies reported that this variant showed abrogated function in the homology directed repair assay, abrogated ubiquitin ligase and weak BARD1 binding activity (Morris_2006, Towler_2013, Ransburgh_2010). This variant is absent in 245588 control chromosomes in gnomAD and was reported in multiple breast cancer patients (Whiley_2014, Kawahara_2004, Tung_2015). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely pathogenic/pathogenic. Taken together, this variant is classified as pathogenic.
Clinical Genetics Karolinska University Hospital,Karolinska University Hospital RCV000484980 SCV001449979 pathogenic not provided 2019-12-12 criteria provided, single submitter clinical testing
Research and Development, ARUP Laboratories RCV001660033 SCV001877790 pathogenic Breast-ovarian cancer, familial 2; Breast-ovarian cancer, familial 1; Hereditary breast and ovarian cancer syndrome 2020-01-20 criteria provided, single submitter curation
Breast Cancer Information Core (BIC) (BRCA1) RCV000111820 SCV000144373 uncertain significance Breast-ovarian cancer, familial 1 2004-02-20 no assertion criteria provided clinical testing
Brotman Baty Institute,University of Washington RCV000111820 SCV001237886 not provided Breast-ovarian cancer, familial 1 no assertion provided in vitro

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.